Background/aims: This study evaluated the efficacy and safety of the first-line chemotherapy regimens in advanced gastric carcinoma (AGC). METHODOGY: In this study, 116 patients who had advanced stage gastric adenocarcinoma were evaluated. The patients receiving Cisplatin/5-Flourouracil (CF) regimen (n=36) were compared with either those receiving Epirubicin/Cispatin/5-Flourouracil (ECF) regimen (n=40) or those receiving Docetaxel/Cispatin/5-Flourouracil (DCF) regimen (n=40).
Results: The overall response rate (ORR) was 18%, 30%, and 40% with CF, ECF, and DCF, respectively. Progression-free survival (PFS) was 4.3, 4.4 and 5.8 months for CF, ECF and DCF, respectively. Although overall survival was similar in all 3 groups, 1-year and 2-year survival rates were better on DCF group compared to the other two groups.
Conclusion: The results of our study suggest that DCF is superior in terms of ORR and PFS in comparison to CF and ECF combinations in AGC.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Comparison of TPF and PF induction chemotherapy combined with cisplatin concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A systematic review and meta-analysis.
Medicine (Baltimore)
January 2025
Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, P.R. China.
Background: The standard of care for locoregionally advanced nasopharyngeal carcinoma (LA-NPC) is induction chemotherapy (ICT) followed by concurrent chemoradiation (CCRT). However, the ideal ICT regimen for LA-NPC remains unclear. We conducted a meta-analysis to evaluate the survival outcomes, responses, and incidences of toxicities between taxane, cisplatin and fluorouracil (TPF) and cisplatin and fluorouracil (PF) ICT regimens plus CCRT in LA-NPC.
View Article and Find Full Text PDFFibrolamellar hepatocellular carcinoma treated with chemotherapy and immunotherapy: a rare entity with unique characteristics.
Rev Esp Enferm Dig
January 2025
Oncología Médica, Hospital Universitario de Burgos, ESPAÑA.
We present the case of a 21-year-old male diagnosed with stage IV fibrolamellar hepatocellular carcinoma, studied by the Oncomine Comprehensive Assay genomic sequencing panel with the finding of the DNAJB1-PRKACA fusion and treated with a combination of chemotherapy and immunotherapy based on cisplatin, 5-fluorouracil, adriamycin and nivolumab.
View Article and Find Full Text PDFThe efficacy of second-line chemotherapy for advanced biliary tract cancer: A systematic review and network meta-analysis.
J Hepatobiliary Pancreat Sci
January 2025
Department of Biomedical Informatics, College of Medicine, Konyang University, Daejeon, Korea.
Background: This network meta-analysis (NMA) aims to provide evidence-based guidance for selecting the second-line chemotherapy for biliary tract cancer (BTC).
Methods: A comprehensive literature search was conducted on PubMed, Cochrane, and EMBASE through July 2024. Inclusion criteria involved: (1) patients underwent second-line chemotherapy following platinum-based first-line therapy, (2) intervention/comparator groups consisted of various chemotherapeutic agents, and (3) outcomes measured as hazard ratio (HR) of overall survival (OS) and progression-free survival (PFS) in randomized controlled trials (RCTs) and cohort studies.
Treatment strategy involving docetaxel plus cisplatin and 5-fluorouracil followed by conversion surgery for locally advanced unresectable/borderline resectable esophageal squamous cell carcinoma.
Dis Esophagus
January 2025
Department of Esophageal Surgery, National Cancer Center, Tokyo, Japan.
Definitive chemoradiotherapy (dCRT) is the standard treatment for unresectable (T4) esophageal squamous cell carcinoma (ESCC), but the prognosis is poor. Borderline resectable (T3br) ESCC has been discussed, but its clinical features and appropriate treatment are unclear. The effects of docetaxel plus cisplatin and 5-fluorouracil (DCF) therapy and subsequent surgery for potentially unresectable ESCC remain controversial.
View Article and Find Full Text PDFMDFGNN-SMMA: prediction of potential small molecule-miRNA associations based on multi-source data fusion and graph neural networks.
BMC Bioinformatics
January 2025
Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing Anzhen Hospital of Capital Medical University, Beijing, 101100, China.
Background: MicroRNAs (miRNAs) are pivotal in the initiation and progression of complex human diseases and have been identified as targets for small molecule (SM) drugs. However, the expensive and time-intensive characteristics of conventional experimental techniques for identifying SM-miRNA associations highlight the necessity for efficient computational methodologies in this field.
Results: In this study, we proposed a deep learning method called Multi-source Data Fusion and Graph Neural Networks for Small Molecule-MiRNA Association (MDFGNN-SMMA) to predict potential SM-miRNA associations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!